Graham Jonathan P 4
4 · AMGEN INC · Filed Feb 10, 2025
Insider Transaction Report
Form 4
AMGEN INCAMGN
Graham Jonathan P
EVP & Gen. Counsel & Sec.
Transactions
- Exercise/Conversion
Common Stock
2025-02-07$156.35/sh+25,045$3,915,786→ 54,032 total - Sale
Common Stock
2025-02-07$293.12/sh−25,045$7,341,123→ 28,987 total - Exercise/Conversion
Nqso (Right to Buy)
2025-02-07−25,045→ 0 totalExercise: $156.35From: 2018-05-03Exp: 2026-05-03→ Common Stock (25,045 underlying)
Footnotes (3)
- [F1]These shares were acquired in connection with the exercise of stock options expiring on May 3, 2026.
- [F2]The price reported is an average price. Full information regarding the number of shares sold at each separate price is available upon request by the SEC staff, the issuer or a security holder of the issuer.
- [F3]These shares include 634 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.